ClinicalTrials.gg
CompletedNCT04742218Updated Aug 9, 2021

Study to Assess the Food Effect of K-877 in Healthy Adult Volunteers

A Phase 1 interventional study of K-877 in Healthy, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-09.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Study is to assess the effects of food on the Pharmacokinetics(PK) of single-dose administration of K-877 in healthy adult volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject provides written before any study-specific evaluation is performed;
  • Subject is a healthy adult male or female volunteer between the ages of 18 and 45 years, inclusive, at screening;
  • Subject has a of 18 to 30 kg/m2, inclusive, at screening
  • Subject meets all inclusion criteria outlined in the clinical study protocol

Exclusion criteria

Exclusion Criteria:

  • Subject is a woman who is pregnant or breastfeeding;
  • Subject has abnormalities in the screening or check-in assessments;
  • Subject has received an drug within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug
  • Subject does not meet any other exclusion criteria outlined in clinical study protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Fasted-Fed

    Single dose of K-877 administered in a fasted condition on Day 1 (Treatment Period 1) and postprandially on Day 4 (Treatment Period 2)

    Drug: K-877

  • Experimental
    Fed-Fasted

    Single dose of K-877 administered postprandially on Day 1 (Treatment Period 1) and in a fasted condition on Day 4 (Treatment Period 2)

    Drug: K-877

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of K-877

    Observed maximum plasma concentration (Cmax)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

  2. AUC0-t of K-877

    Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (AUC0-t)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

  3. AUC0-inf of K-877

    Area under the plasma concentration versus time curve from time 0 extrapolated to infinity (AUC0-inf)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

Secondary outcomes

  1. Tmax of K-877

    Time to reach the observed maximum (peak) plasma concentration (Tmax)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

  2. MRT0-t of K-877

    Mean residence time from time 0 to the time of the last quantifiable concentration (MRT0-t)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

  3. MRT0-inf of K-877

    Mean residence time from time 0 extrapolated to infinity (MRT0-inf)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

  4. t1/2 of K-877

    Terminal elimination half-life (t1/2)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

  5. Kel of K-877

    Terminal elimination rate constant (Kel)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

  6. CL/F of K-877

    Apparent oral clearance (CL/F)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

  7. Vd/F of K-877

    Apparent volume of distribution (Vd/F)

    Time frame: pre-dose (within 1 hour before dosing and at pre-meal in case of fed condition) and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Days 1 and 4

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: Baseline to Day 6

07

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Apr 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Feb 8, 2021
StartActual
Jan 13, 2021
Primary completionActual
Apr 11, 2021
CompletionActual
Apr 11, 2021
Last update
Aug 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04742218
Responsible party
Sponsor
First posted
Feb 8, 2021
Start date
Jan 13, 2021
Primary completion
Apr 11, 2021
Completion
Apr 11, 2021
Last update
Aug 9, 2021

Study contacts

Shona Pendse, MD, MMSc
study chair · Kowa Research Institute, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemafibrate

Start the discussion